You are viewing the site in preview mode
Skip to main content
| |
No Neonatal Hypoglycemia
|
Neonatal Hypoglycemia
|
P value
|
AOR
|
95%CI
|
P value
|
|---|
|
Cases (n)
|
36 (38.3)
|
58 (61.7)
| | | | |
|
Maternal age over 35 (n)
|
7 (19.4)
|
24 (41.4)
|
0.042
|
3.385
|
1.082–10.588
|
0.036
|
|
Maternal height (cm)
|
158.5 (140.0 – 169.0)
|
158.0 (146.0 – 174.0)
|
0.703
| | | |
|
Pre-pregnancy BMI (kg/m2)
|
20.4 (15.3 – 26.6)
|
20.3 (17.0 – 33.8)
|
0.876
| | | |
|
Maternal weight gain (kg)
|
8.0 (1.5 – 18.0)
|
9.0 (3.0 – 17.5)
|
0.117
| | | |
|
Gestational age (wk/day)
|
37 /1 (36/0 – 38/4)
|
37/0 (36/0 – 37/6)
|
0.598
| | | |
|
Birth weight < 2500 g (n)
|
7 (19.4)
|
26 (44.8)
|
0.015
|
2.479
|
0.774–7.942
|
0.126
|
|
Twin birth (n)
|
6 (16.7)
|
25 (43.1)
|
0.012
|
2.417
|
0.743–7.863
|
0.143
|
|
Administration of magnesium sulfate (n)
|
4 (11.1)
|
11 (19.0)
|
0.393
| | | |
|
Administration length (day)
|
43.5 (0.04 – 134.0)
|
38.5 (6.0 – 147.0)
|
0.694
| | | |
|
Final administration dose rate (μg/min)
|
65.0 (33.0 – 192.3)
|
93.3 (32.1 – 192.3)
|
0.048
|
0.999
|
0.987–1.011
|
0.878
|
|
Interval (hr)
|
12.5 (0.0 – 154.0)
|
1.3 (0.0 – 167.9)
|
< 0.001
|
0.974
|
0.953–0.996
|
0.020
|
- Data are expressed as median (min-max) or number (%). The final administration dose rate is that at the time of stopping maternal intravenous administration of RD. The interval is the time period from stopping maternal intravenous administration of RD to delivery
- RD: ritodrine hydrochloride, AOR adjusted odds ratio, CI confidence interval
